Thrombolysis: Mechanisms, Agents, and Clinical Applications

Thrombolysis (fibrinolysis) is the pharmacologic or mechanical dissolution of a thrombus (blood clot) to restore perfusion.

Mechanism

Plasminogen activators convert plasminogen → plasmin → degrades fibrin mesh → clot lysis → D-dimer release.

Pharmacologic Agents

AgentTypeKey Features
Alteplase (tPA)Recombinant tissue plasminogen activatorFibrin-specific; short half-life (5 min); standard for acute ischemic stroke (<4.5 hr), STEMI, massive PE
Tenecteplase (TNK)Modified tPALonger half-life (20 min); single bolus; preferred for STEMI; non-inferior for stroke
Reteplase (rPA)Deletion mutant tPALess fibrin-specific; double bolus; STEMI
StreptokinaseBacterial proteinNon-fibrin-specific; antigenic; low cost; developing world use
UrokinaseHuman urine / recombinantDirect plasminogen activator; catheter-directed thrombolysis (CDT)

Clinical Indications

  • Acute Ischemic Stroke: IV alteplase 0.9 mg/kg (max 90 mg) within 4.5 hr (extended criteria per DAWN/DEFUSE-3).
  • STEMI: If PCI >120 min; tenecteplase preferred.
  • Massive PE (hemodynamic instability): IV alteplase 100 mg over 2 hr.
  • Catheter-Directed Thrombolysis (CDT): DVT (iliofemoral), arterial occlusion, dialysis access thrombosis – urokinase/alteplase infused locally.

Contraindications (Absolute)

  • Active internal bleeding, recent surgery/trauma (<3 mo), intracranial neoplasm, hemorrhagic stroke history, severe uncontrolled HTN (>180/110), known bleeding diathesis.

Risk-benefit assessment is time-critical; protocols mandate rapid door-to-needle times.

Blood Disorders - Related Articles